Methods of selecting, based on polymorphisms, an inflammatory bowel disease subject for treatment with an anti-TL1A antibody
US12215147B2 · kind B2 · utility
1Cited by
62References
45Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Aug 23, 2021 |
| Grant date | Feb 4, 2025 |
| Priority date | — |
| Expiry date | Nov 21, 2041 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12Q2600/156
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided are methods, systems, and kits for selecting a patient for treatment with a therapeutic agent based on a presence of a genotype associated with a positive therapeutic response to the therapeutic agent. The therapeutic agent, in some embodiments, is an inhibitor of TL1A activity or expression, such as for example, an anti-TL1A antibody.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.